Trial Profile
A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients With HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Trastuzumab
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 12 Nov 2019 Status changed from active, no longer recruiting to completed.
- 11 Feb 2019 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 06 Sep 2018 Planned End Date changed from 1 Dec 2018 to 31 Dec 2018.